ArticleBiomacromolecules2022
Dissolving Microneedle Delivery of a Prophylactic HPV Vaccine.
Article in Biomacromolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- An innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.Acta pharmaceutica Sinica. B · 2026Article
- Global Perspectives on HPV Vaccination: Achievements, Challenges, and Lessons from the Brazilian Experience.Vaccines · 2025Review
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.International journal of nanomedicine · 2025Article
- Advances in clinical applications of microneedle.Frontiers in pharmacology · 2025Review
- Development and Evaluation of Five-in-One Vaccine Microneedle Array Patch for Diphtheria, Tetanus, Pertussis, Hepatitis B, andPharmaceutics · 2024Article
- Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review.Vaccines · 2024Review
- Anti-Nociceptive Effect of Sufentanil Polymeric Dissolving Microneedle on Male Mice by Hot Plate TechniqueIranian biomedical journal · 2024Article
- Fabrication of lidocaine-loaded polymer dissolving microneedles for rapid and prolonged local anesthesia.Biomedical microdevices · 2024Article
- Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Responsive Microneedles as a New Platform for Precision Immunotherapy.Pharmaceutics · 2023Review
- Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.Pharmaceutics · 2023Review
- Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant.Bioconjugate chemistry · 2023Article
- Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Carrier gas triggered controlled biolistic delivery of DNA and protein therapeutics from metal-organic frameworks.Chemical science · 2022Article
- Film-trigger applicator (FTA) for improved skin penetration of microneedle using punching force of carboxymethyl cellulose film acting as a microneedle applicator.Biomaterials research · 2022Article
- Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women.Medical microbiology and immunology · 2022Article
- Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Prophylactic vaccines capable of preventing human papillomavirus (HPV) infections are still inaccessible to a vast majority of the global population due to their high cost and challenges related to multiple administrations performed in a medical setting. In an effort to improve distribution and administration, we have developed dissolvable microneedles loaded with a thermally stable HPV vaccine candidate consisting of Qβ virus-like particles (VLPs) displaying a highly conserved epitope from the L2 protein of HPV (Qβ-HPV). Polymeric microneedle delivery of Qβ-HPV produces similar amounts of anti-HPV16 L2 IgG antibodies compared to traditional subcutaneous injection while delivering a much smaller amount of intradermal dose. However, a dose sparing effect was found. Furthermore, immunization yielded neutralizing antibody responses in a HPV pseudovirus assay. The vaccine candidate was confirmed to be stable at room temperature after storage for several months, potentially mitigating many of the challenges associated with cold-chain distribution. The ease of self-administration and minimal invasiveness of such microneedle patch vaccines may enable wide-scale distribution of the HPV vaccine and lead to higher patient compliance. The Qβ VLP and its delivery technology is a plug-and-play system that could serve as a universal platform with a broad range of applications. Qβ VLPs may be stockpiled for conjugation to a wide range of epitopes, which are then packaged and delivered directly to the patient via noninvasive microneedle patches. Such a system paves the way for rapid distribution and self-administration of vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.